Novo Nordisk to invest over $2B in drug ingredient production

Danish drugmaker Novo Nordisk will spend 15.9 billion Danish kroner, or about $2.3 billion, to expand manufacturing capacity for future chronic disease medicines at a site north of Copenhagen, Denmark.